Title
AtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus.

Permalink
https://escholarship.org/uc/item/62d818v0

Journal
mBio, 10(2)

ISSN
2150-7511

Authors
Paul, Sanjoy
Stamnes, Mark
Thomas, Grace Heredge
et al.

Publication Date
2019-03-12

DOI
10.1128/mBio.02563-18

Peer reviewed
AtrR Is an Essential Determinant of Azole Resistance in
Aspergillus fumigatus

Sanjoy Paul,a Mark Stamnes,a Grace Heredge Thomas,a Hong Liu,b Daisuke Hagiwara,d Katsuya Gomi,e Scott G. Filler,b,c W. Scott Moye-Rowleya

aDepartment of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
bDivision of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA
cDavid Geffen School of Medicine at UCLA, Los Angeles, California, USA
dFaculty of Life and Environmental Sciences, University of Tsukuba, Ibaraki, Japan
eGraduate School of Agricultural Science, Tohoku University, Sendai, Japan

ABSTRACT Aspergillosis associated with azole-resistant Aspergillus fumigatus has a mortality rate that can approach 90% in certain patient populations. The best-understood avenue for azole resistance involves changes in the cyp51A gene that encodes the target of azole drugs, lanosterol α-14 demethylase. The most common azole resistance allele currently described is a linked change corresponding to a change in the coding sequence of cyp51A and a duplication of a 34-bp region in the promoter leading to a tandem repeat (TR). Our previous studies identified a positively acting transcription factor called AtrR that binds to the promoter of cyp51A as well as that of an important membrane transporter protein gene called abcG1. In this work, we characterize two different mutant alleles of atrR, either an overproducing or an epitope-tagged form, causing constitutive activation of this factor. Using an epitope-tagged allele of atrR for chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq), the genomic binding sites for AtrR were determined. Close to 900 genes were found to have an AtrR response element (ATRE) in their promoter regions. Transcriptome evaluation by RNA sequencing (RNA-seq) indicated that both alleles led to elevated transcription of a subset of target genes. An electrophoretic mobility shift assay and DNase I protection mapping localized the ATREs in both the abcG1 and cyp51A promoters. The ATRE in cyp51A was located within the 34-bp repeat element. Virulence in a murine model was compromised when AtrR was either deleted or overproduced, indicating that the proper dosage of this factor is key for pathogenesis.

IMPORTANCE Aspergillus fumigatus is the major filamentous fungal pathogen in humans. Infections associated with A. fumigatus are often treated with azole drugs, but resistance to these antifungal agents is increasing. Mortality from aspergillosis associated with azole-resistant fungi is extremely high. Previous work has identified transcriptional control of the azole drug target-encoding gene cyp51A as an important contributor to resistance in A. fumigatus. Here, we demonstrate that the transcription factor AtrR binds to a region in the cyp51A promoter that is associated with alleles of this gene conferring clinically important azole resistance. Using high-throughput genomic technologies, we also uncover a large suite of target genes controlled by AtrR. These data indicate that AtrR coordinately regulates many different processes involved in drug resistance, metabolism, and virulence. Our new understanding of AtrR function provides important new insight into the pathogenesis of A. fumigatus.

KEYWORDS ABC transporters, antifungal resistance, Aspergillus fumigatus, molecular genetics, transcriptional regulation
Infections associated with azole-resistant forms of *Aspergillus fumigatus* have a mortality rate that can approach 90% in particular patient populations (discussed in reference 1). This places a high priority on understanding the molecular basis of development of this problematic phenotype. Extensive studies from several laboratories have provided support for the prevalence of a compound mutation in the *cyp51A* gene that encodes the target enzyme of azole drugs, lanosterol \( \alpha \)-14 demethylase (recently reviewed in reference 2). This interesting compound mutation consists of a change within the *cyp51A* open reading frame that replaces a leucine at position 98 with a histidine residue (L98H) and contains a duplication of a 34-bp region in the promoter (tandem repeat of 34 bp [TR\( _{34} \)] (3). These linked changes cause elevated *cyp51A* mRNA levels and produce an altered enzyme that is believed to have a defect in azole drug binding (4, 5). Both of these alterations must be present for the synergistic increase in azole resistance to occur (6). Other alterations in the *cyp51A* promoter that duplicate similar regions have been described, with these changes sharing the common feature of elevating transcription of *cyp51A* (7, 8).

The requirement for increased transcription of *cyp51A* makes analyzing the transcriptional control mechanisms of this gene an important step in developing strategies to interfere with acquisition of azole resistance. A recent detailed analysis has provided new insights into the function of both the wild-type *cyp51A* promoter and the TR\( _{34} \) derivative (9). A binding site for the important positive transcriptional regulator of ergosterol biosynthetic enzyme-encoding genes called SrbA was found to bind to the 34-bp region, and this binding element was designated the SrbA response element (SRE) (9). Two SREs were localized to the 34-bp region and shown to be duplicated in the TR\( _{34} \) mutation. Additional regulatory sites have been documented for the negatively acting factors CCAAT-binding complex (CBC) and HapX (10). The CBC is a complex of three proteins (HapB, HapC, and HapE) (reviewed in reference 11) that act along with HapX to repress the transcription of *cyp51A* and a number of other loci encoding enzymes required for ergosterol production and iron homeostasis (12). Mutation of either the *hapE* or *hapX* gene led to elevated azole resistance and increased *cyp51A* transcription (9).

A new participant in the transcriptional control of *cyp51A* gene expression was recently discovered to be a Zn\( _{2} \)Cys\( _{6} \) cluster-containing transcription factor that was able to elevate azole resistance when overproduced in *Aspergillus oryzae* (13). This factor, designated ABC transporter regulator, or AtrR, was found to be present in *A. fumigatus* and to be required for normal azole tolerance. AtrR was linked to regulation of both *cyp51A* and the ATP-binding cassette (ABC) transporter-encoding gene *abcG1* (also known as [aka] *cdr1B*) by two pieces of evidence. First, strains lacking atrR failed to drive normal transcription of either *cyp51A* or *abcG1*. Second, chromatin immunoprecipitation (ChIP) experiments demonstrated that AtrR bound to both the *cyp51A* and *abcG1* promoter regions. However, the sequence of the AtrR response element (ATRE), its relationship to the SRE, and the genomic target sites of this factor remained among the gaps in our knowledge.

Here, we report the generation of two hypermorphic or hyperactive alleles of *atrR*, as well as identification of the suite of AtrR-responsive genes in vivo using chromatin immunoprecipitation coupled with high-throughput DNA sequencing (ChIP-seq). The sequence of the ATRE was identified from these analyses and confirmed by a combination of DNase I footprinting, electrophoretic mobility shift assays (EMSA), and mutagenesis. AtrR and SrbA both bind to the critical 34-bp region of *cyp51A* and are likely to cooperate to drive the transcription of this key azole resistance determinant, while only AtrR appears to control *abcG1* transcription.

**RESULTS**

Generation of two hypermorphic alleles of *atrR*. We previously generated an epitope-tagged form of *atrR* corresponding to the wild-type gene containing a C-terminal insertion of a 3× hemagglutinin (3× HA) tag (13). More recently, we replaced the endogenous *atrR* promoter with the cognate region from the highly
transcribed hspA gene (14). Based on RNA-seq analyses (15), we estimate that this hspA allele has the potential to overproduce atrR mRNA by at least 10-fold. To compare the functions of these different forms of atrR, we placed appropriate transformants on minimal medium lacking or containing 0.1 g/ml voriconazole. We also included isogenic wild-type atrRΔ null cells for comparison along with an hspA-atrR-3X HA allele used earlier. Plates were incubated at 37°C to evaluate the relative resistance conferred by these different atrR alleles (Fig. 1A).

The presence of the hspA promoter upstream of atrR, either tagged with 3X HA or untagged, strongly elevated voriconazole resistance. Interestingly, even insertion of the 3X HA epitope tag alone was sufficient to elevate azole resistance. These data suggest that fusion of foreign sequences to the C terminus or overproduction of AtrR (see
below) both represent means of overcoming the normal control of transactivation by this transcription factor.

Work from several labs has implicated an ATP-binding cassette (ABC) transporter-encoding gene, here called abcG1, as being an important determinant inazole resistance (16, 17), as well as being a target gene for AtrR regulation (13). To examine the epistatic relationship between AtrR and abcG1, we constructed isogenic hspA-atrR strains that contained or lacked a copy of abcG1. We compared these strains for resistance to voriconazole as described above along with wild-type and abcG1Δ control strains (Fig. 1B).

A loss of abcG1 strongly depressed voriconazole resistance in a strain overproducing AtrR. However, even in the absence of abcG1, overproduction of AtrR was still able to elevateazole resistance. This is consistent with abcG1 being an important but not exclusive target gene of AtrR impacting voriconazole resistance.

Expression of abcG1 responds to hypermorphic alleles of atrR. To confirm that increased AtrR levels led to increased expression of AbcG1, we directly assayed the expression of these two proteins using polyclonal antibodies directed against recombinant forms of each. Isogenic wild-type and atrRΔ strains were grown in minimal medium, along with transformants containing the epitope-tagged atrR allele (atrR-3×HA) or strains with the hspa promoter in place of the wild-type atrR promoter driving the native (hspa-atrR) or epitope-tagged (hspa-atrR-3×HA) allele. Whole-cell protein extracts were prepared from these strains and analyzed by Western blotting using anti-AtrR or anti-AbcG1 antiserum.

AtrR was seen as a 100-kDa protein in extracts from wild-type cells that was eliminated in atrRΔ cells (Fig. 2A). The presence of the hspa promoter in place of the wild-type atrR promoter led to the overproduction of AtrR. The epitope-tagged form of AtrR was expressed at levels similar to those in the wild type, irrespective of being under wild-type or hspa promoter control. Our use of the anti-AtrR antibody allowed facile comparison of levels of tagged and untagged transcription factors. The size of this polypeptide was increased by the presence of the 3× HA tag, as expected; however, the steady-state level of this form of AtrR was not increased when under hspa promoter control, unlike the effect seen for the wild-type factor. These data confirm that the wild-type protein was overproduced when driven from the hspa promoter, as suggested above.

The expression of AbcG1 was strongly responsive to the presence of atrR (Fig. 2B), consistent with earlier data (13). Both overproduction of the native AtrR protein and the presence of the epitope-tagged atrR allele increased the expression of AbcG1.

We next measured expression levels of the mRNA for atrR and abcG1 to determine if these changes at the protein level correlated with the expected alterations in gene transcription. Wild-type and atrRΔ, atrR-3×HA, and hspa-atrR mutant strains were grown to mid-log phase, total RNA was prepared, and quantitative reverse transcription-PCR (qRT-PCR) was used to evaluate mRNA levels for atrR and abcG1.

The transcription of atrR was increased in the presence of the hspa-atrR allele but was not altered by the insertion of the epitope tag at the C terminus of the native gene (Fig. 2C). In contrast, abcG1 transcription was similarly increased by the presence of either hypermorphic allele of atrR (Fig. 2D). We suggest from these data that the causes of the increased abcG1 expression induced by the presence of the epitope-tagged or the hspa-driven allele of atrR are different and discuss this more fully below.

Genomic target genes of AtrR. We have previously shown that AtrR binds directly to the promoters of abcG1 and cyp51A in vivo by single-gene chromatin immunoprecipitation (ChIP) analyses (13). To determine the range of target genes of AtrR in the entire A. fumigatus genome, we carried out ChIP coupled with high-throughput sequencing (ChIP-seq) using the atrR-3×HA and hspa-atrR-3×HA strains. Wild-type (negative control), atrR-3×HA, and hspa-atrR-3×HA strains were grown to mid-log phase and cross-linked chromatin prepared, as described previously (18). Isolated chromatin prepared for next-generation sequencing using standard methods (19) and
the sequencing reads were mapped to the *A. fumigatus* genome sequence. Significantly increased read depth peaks were called by comparison to untagged wild-type controls and assessed for proximity to annotated protein-coding genes. We found nearly 900 peaks for AtrR binding in the promoter regions of protein-coding genes. Plots of representative ChIP densities are shown in Fig. 3A.

As expected from our single-gene ChIP data (13), we found significant AtrR binding to regions upstream of both *abcG1* and *cyp51A*. Interestingly, we also found evidence...
for AtrR binding to the promoter regions of both the \textit{srbA} and \textit{atrR} genes themselves. The \textit{srbA} gene encodes the previously characterized sterol response transcription factor SrbA (20), while AtrR binding to its own promoter suggests the possibility that \textit{atrR} is autoregulated.

As the specific element recognized by AtrR is not well understood, we compared the sequences of all the detected ChIP-seq peaks using the algorithm MEME-ChIP (21). This algorithm compares sequences surrounding each of the annotated peak summits to search for a shared common element. This analysis predicted the presence of two most common shared elements shown in Fig. 3B. We believe that motif 1 represents the half-site of an AtrR response element (ATRE), while motif 2 corresponds to the binding site for the SrbA transcription factor (SrbA response element [SRE]). Motif 1 was present in approximately 600 of the ChIP-seq peaks, while motif 2 was found in ~400 peaks. Interestingly, these were present at the same promoter in roughly 100 genes. These sequences are analyzed in more detail below.

We next validated that DNA regions containing these different ATREs could be bound by a recombinant form of AtrR corresponding to the N-terminal DNA-binding domain of the factor. In all cases, each probe was produced by PCR amplification from
A. fumigatus genomic DNA, radiolabeled, and incubated with the bacterially produced AtrR alone or in the presence of a 40-fold molar excess of the unlabeled probe. We also used a region from the promoter of the actin-encoding actA gene as a control for nonspecific binding. After formation of protein-DNA complexes, these reaction mixtures were separated on a nondenaturing 5% polyacrylamide gel and detected by autoradiography (Fig. 3C).

AtrR was able to bind to all these target genes containing ATREs, while no binding was seen to the actA promoter. These data support the coincidence of ChIP-seq binding peaks and bona fide ATREs in the A. fumigatus genome.

Comparison of the functions of the proteins produced from these potential regulatory targets of AtrR indicated that several gene ontology (GO) terms were enriched. The most enriched GO terms included sequence-specific DNA binding, plasma membrane, and several metabolic processes (see Fig. S1 in the supplemental material). The list of sequence-specific DNA-binding protein-encoding genes consisted of 42 genes and included loci previously shown to influence azole resistance, such as srbA (22), srbB (18), and yap1 (23). This large number (42) (see Table S1) of transcriptional regulators suggests the possibility that their regulation by AtrR might lead to an amplification of the effect of AtrR through the action of these downstream regulators, a suggestion we support below.

Previous ChIP-seq experiments have identified the potential targets for SrbA gene regulation (18). Since cyp51A has already been demonstrated to be a target gene for both SrbA and AtrR regulation (13), we wondered if other genes might be regulated by both AtrR and SrbA (Fig. S2). Comparing the ChIP-seq data for these factors, we found that 51 genes were present in lists of ChIP-seq-positive targets for both AtrR and SrbA (Fig. 4A). These include ergosterol biosynthetic genes like cyp51A, cyp51B, erg3A, erg5, and erg25 (recently reviewed in reference 2), transcription factors such as srbA itself and srbB, iron uptake (ftrA) (24), and a heme biosynthesis gene (hem13) (20). As the total number of SrbA-regulated genes was estimated to be 126, almost 50% of these are also predicted to contain ATREs, indicating extensive overlap between these two transcription factors. This extensive overlap helps explain why the SRE was the second most common enriched motif found in our MEME-ChIP analysis.

Transcriptomic profiling of hyperactive alleles of atrR. Since a large number of genes were predicted to have binding sites for AtrR in their promoters, we wanted to determine the range of genes that responded to the two different hyperactive alleles, the hspA-overproduction derivative and the 3× HA-tagged form. Isogenic wild-type and atrRΔ, hspa-atrR, and atrR-3× HA mutant strains were grown in minimal medium. Total RNA was prepared and analyzed by RNA-seq, as described previously (15). The top 50 upregulated genes clustered by regulatory pattern are shown in Fig. 5A.

A total of 633 genes were upregulated by at least 2-fold in the presence of the hspa-atrR, while the epitope-tagged allele exhibited 293 genes that were upregulated by this same degree. Importantly, only around 20% of these upregulated genes were also found to be positive for the presence of an ATRE as assessed by ChIP-seq. The most highly induced gene in the presence of either hyperactive allele was the abcG1 gene. GO terms for the top 100 genes in the cluster analysis showed enrichment for genes involved in oleate metabolism and gliotoxin biosynthesis, but these two groups only involved 5 genes total (data not shown). We also compared the effects seen when atrR was deleted with results from our earlier study (13). Of the 200 genes that showed the greatest reduction in expression upon loss of atrR, only approximately 10% were seen to overlap between the current RNA-seq measurement and in the previous assay (13). This is likely due to cells being grown as a biofilm in these experiments, while in the previous assays, cells were grown planktonically. Large differences in transcription have previously been reported in a comparison of genes grown under these different conditions (15).

The overlap between upregulated genes in either hyperactive allele was compared along with the total number of ChIP-positive genes (Fig. 5B). Only 38 (2.5% of the total)
genes were upregulated in the presence of one or both hyperactive alleles and contained ATREs. Additionally, the effect of overproduction of wild-type AtrR (in the hspA-arr fusion) had a stronger phenotypic response than did the presence of the atrR-3 HA allele, as evidenced by the larger number of genes that were induced in response to the hspA-atrR allele. These data support the view that much of the AtrR-responsive regulon occurs via indirect effects through the engagement of other transcription factor networks (like SrbA) and others identified in the ChIP-seq analysis described above. This also supports the suggestion made above that the effects of AtrR are amplified via induction of the large number of transcription factor-encoding genes containing ATREs.

FIG 4 Shared target genes of AtrR and SrbA. (A) A diagram representing the genes that contain both an ATRE as predicted from the ChIP-seq data reported here and a SRE as found in reference 18. (B) FungiFun2 (42) was used to identify GO terms enriched in these genes. SREBP, SRE binding protein.
A. | Input ID | Product Description
--- | --- | ---
AFUA_1G14330 | Putative ABC transporter
AFUA_4G00450 | Unknown
AFUA_1G09410 | Predicted hydrolase activity
AFUA_3G03230 | Predicted role in metabolic process
AFUA_1G17710 | Fungal Zn(2)-Cys(6) binuclear cluster domain protein
AFUA_6G00310 | Putative serine carboxypeptidase
AFUA_6G14550 | Predicted hydrolase activity
AFUA_4G00470 | Unknown
AFUA_6G14580 | RNA pol II transcription factor
AFUA_5G01200 | Predicted adhesin-like protein
AFUA_4G13780 | Predicted oxidoreductase activity
AFUA_4G13800 | Sialidase
AFUA_6G09720 | N-methyltransferase glnN
AFUA_6G09730 | Cytochrome P450 monooxygenase gllF
AFUA_6G09740 | Thioredoxin reductase gllT
AFUA_6G09745 | Unknown
AFUA_3G00370 | Putative phosphotolase
AFUA_4G03610 | Putative phosphate:H+ symporter
AFUA_8G01290 | Unknown
AFUA_2G03780 | Unknown
AFUA_2G03780 | Predicted glutathione S transferase
AFUA_3G14980 | Extracellular chitosanase
AFUA_4G03420 | Protein of unknown function
AFUA_4G09210 | Transmembrane transporter
AFUA_5G00380 | Ortholog(s) have intracellular localization
AFUA_8G02220 | Major facilitator superfamily (MFS) toxin efflux pump
AFUA_8G04560 | Unknown
AFUA_8G06050 | Predicted oxidoreductase activity
AFUA_3G15280 | Methyltransferase, putative
AFUA_5G00710 | Putative gamma-aminobutyric acid (GABA) permease
AFUA_6G00740 | Predicted oxidoreductase
AFUA_6G03440 | Fructosyl amino acid oxidase, putative
AFUA_6G03460 | Fumipyrroline biosynthesis protein C
AFUA_6G10680 | Putative ATP citrate lyase, subunit 1
AFUA_6G11680 | Putative ATP citrate lyase subunit
AFUA_6G11880 | Unknown
AFUA_8G00670 | Unknown
AFUA_2G15240 | Small oligopeptide transporter
AFUA_5G00590 | Putative integral membrane protein
AFUA_5G01500 | Predicted oxidoreductase
AFUA_5G15060 | Unknown
AFUA_6G03490 | Aromatic hydrolase fmpF
AFUA_6G03510 | Predictive oxidoreductase
AFUA_7G06840 | Putative class III amino transferase
AFUA_6G00210 | Brevisaminide F prenyltransferase
AFUA_6G00680 | Unknown
AFUA_8G01390 | Predicted hydrolase activity
AFUA_8G06520 | Predicted protein-arginine deiminase

B. FIG 5  RNA-seq analysis of atrR alleles. (A) A heat map of the RNA-seq data obtained from use of RNA prepared from isogenic wild-type, atrRΔ (null) mutant, hspA-atrR (hspA) mutant, and atrR-3X HA (HA) strains is shown. Colors represent the log2 values of the ratio of RNA levels detected in the indicated strains at the top relative to those present in the wild-type cells. The presence of an ATRE in the promoter region of each gene is indicated by the + symbol. (B) Venn diagram showing the union of all ChIP-seq-positive genes with the genes corresponding to transcripts overproduced by a log2 of 1 or greater in strains containing either hyperactive allele of atrR. The percent value represents the portion each category makes up of the total number of genes analyzed here. pol, polymerase.
A hyperactive allele of atrR cannot suppress phenotypes of a srbAΔ strain. While the data described above provided several links between AtrR and SrbA functions, we wanted to examine the interaction of these two important genes that impact related in vivo processes. We employed genetic epistasis to determine if the hypermorphic hspA-atrR allele was capable of suppressing the well-described azole sensitivity of a srbAΔ null strain. Isogenic wild-type and atrRΔ, srbAΔ, hspA-atrR, and hspA-atrR srbAΔ mutant strains were grown and tested using a disk diffusion assay. Plates were incubated at 37°C and photographed (Fig. 6).

While overproduction of AtrR strongly elevated voriconazole resistance in an otherwise wild-type genetic background, the loss of srbA completely blocked this effect. The epistasis of srbA to the hspA-atrR allele was also seen when testing for fluconazole resistance or hypoxic growth (data not shown). Both of these genes are required for normal azole resistance and driving high-level expression of AtrR cannot suppress the need for SrbA under these conditions.

Interaction of AtrR with the cyp51A 34-bp element. While the ChIP-seq data implicated a region in the 34-bp region of the cyp51A promoter as the binding site for AtrR, we wanted to precisely locate this element and support our identification of the ATRE. Additionally, we wanted to compare where SrbA bound to the 34-bp repeat with the ATRE and previous data using a plasmon resonance approach (9). We used our recombinant forms of SrbA and AtrR in a DNase I protection assay on the cyp51A promoter region. Purine- and pyrimidine-specific reactions were also carried out on this same probe to provide a means of mapping protected areas back to the DNA sequence. Limited DNase I digestions were performed on the free probe or this same probe bound to SrbA and/or AtrR. All samples were then electrophoresed through denaturing acrylamide gels and DNA fragments detected by autoradiography (Fig. 7A).

AtrR protected a roughly 25-bp region containing the ATRE from DNase I cleavage. This ATRE was located immediately upstream of the CBC-binding site mapped earlier (9). SrbA bound to an SRE that was previously mapped and designated SRE1. A downstream SRE that overlapped with the ATRE, called SRE2, was not protected from DNase I cleavage in this assay. This likely reflects the finding that the $K_d$ (dissociation
constant) for SrbA binding to SRE2 is 10-fold higher than for SRE1 (9). Together, these data suggest that only SRE1 may play a relevant role in vivo.

To probe the specific sequence elements in the ATRE that are important for AtrR recognition, we used an electrophoretic mobility shift assay (EMSA) with the 34-bp region of cyp51A as the probe. This was chemically synthesized with a biotin moiety attached to the 5'-end of each oligonucleotide used to generate the probe. We also produced nonbiotinylated competitor oligonucleotides corresponding to a mutant with a 6-bp substitution in the region between the two CCG repeats (EcoRI), a 4-bp

**FIG 7** AtrR binding to cyp51A. (A) A 5'-end-labeled probe corresponding to the cyp51A promoter region was prepared and used in Maxam-Gilbert chemical sequencing reactions (AG, purine residues; CT, pyrimidine residues) to generate a size standard to allow localization of the binding sites for AtrR and SrbA. This same probe was then used in a standard DNase I protection assay with the addition of recombinant forms of AtrR or SrbA where indicated. The drawing on the left represents the sequence elements of interest. The gray bar denotes the bounds of the 34-bp region that is duplicated in the TR34 promoter mutation. The double-headed arrow labeled CBC indicates the previously shown binding site for the CAAT-binding complex (9), and the sequence in blue represents a previously mapped SrbA response element (SRE) from this same earlier study. The AtrR response element (ATRE) is indicated with the two CGG repeats in green text. (B) Electrophoretic mobility shift assay (EMSA) analysis of sequence requirements for AtrR binding. A biotin-labeled form of the 34-bp element from cyp51A was used as a probe for all these EMSA reactions. Recombinant forms of SrbA or AtrR were added to this probe in the absence or presence of the indicated nonbiotinylated competitor DNAs listed at the bottom. Protein-DNA complexes formed by SrbA. The locations of the SRE and ATRE are shown as in panel A, with mutant residues indicated by red text. All competitors were present at 10-fold molar excess.
replacement mutant in the upstream CCG repeat (SphI), or with a mutant lacking both copies of the CCG repeat (DM). These unlabeled oligonucleotides were used as competitors to determine if they retained the ability to block AtrR binding to the biotinylated 34-bp probe. Recombinant proteins were added to the biotinylated probe in the absence or the presence of the indicated competitor DNAs. After binding, free probe and protein-probe complexes were resolved on nondenaturing acrylamide gels, transferred to nylon membranes, and visualized by blotting with an IRDye-labeled streptavidin (Fig. 7B).

AtrR formed a complex with the 34-bp probe that could be competed away using either a 42-bp version of this promoter fragment or the same 42-bp competitor containing the 6-bp mutation between the two CCG repeats. Importantly, mutant competitors lacking either one (SphI) or both CCG repeats (DM) could not compete. These data confirm the importance of these CCG repeats in normal DNA binding of the ATRE by AtrR.

A region containing tandem ATREs is important for normal abcG1 expression. We previously described the use of a firefly luciferase reporter system to compare expression of the abcG1 gene and a homologue called abcG4 (Afu2g15130). The region 1,000 bp upstream of the ATG codon for both these genes was used to drive luciferase expression, and the resulting fusion constructs produced similar low-level luciferase expression (14). This was surprising since qRT-PCR analyses of these same gene indicated that abcG1 mRNA was 4-fold higher than that of abcG4.

Our finding of AtrR binding to a region more than 1,000 bp upstream of the ATG by ChIP-seq suggested a possible explanation for this observation, as we may have inadvertently truncated the abcG1 promoter in our original construct. To test this hypothesis, we produced a new fusion construct that extended to 1,300 bp upstream of the ATG and contained the predicted ATREs for abcG1. We introduced this longer construct, along with our original fusion and a no-promoter control into wild-type, atrRΔ mutant, and hspA-atrR mutant cells. Representative transformants were grown overnight and then levels of abcG1 promoter-driven luciferase assayed (Fig. 8A).

The 1.3-kb promoter region was expressed more highly than the 1-kb construct in all genetic backgrounds. This is most dramatically seen in the presence of the hypermorphic allele of atrR in which luciferase levels of the 1.3-kb reporter construct were nearly 4-fold elevated compared to those of the 1-kb fusion gene. The increase in luciferase levels when the 1-kb construct was assayed in the hspA-atrR background compared to the wild-type was less than 2-fold. This supports the notion that the region from 100 to 1,300 bp upstream of the ATG of abcG1 may contain the AtrR-responsive region.

Sequence inspection of this same upstream region showed the presence of two potential ATREs (see Table 1). We carried out DNase I protection analysis of this portion of the abcG1 promoter using recombinant AtrR as described above for cyp51A (Fig. 8B). This analysis demonstrated the presence of two ATREs in this region of the abcG1 promoter and provides a molecular understanding for the defective AtrR response of the 1-kb reporter gene that lacks these two elements.

The expression level of AtrR is important during pathogenesis. A loss of atrR was previously shown to strongly reduce virulence in a mouse model of aspergillosis (13). Here, we have described two new hyperactive alleles of atrR and wanted to determine what impact these would have on virulence in this murine model. We used a lung inhalation model (25) to test the impact of loss of a key AtrR target gene, the ABC transporter-encoding abcG1 locus, or overproduction of AtrR itself (hspA-atrR) on fungal virulence. Mice were challenged with these strains along with an isogenic wild-type control and survival followed over an 11-day time course (Fig. 9).

We found that elevating the expression of AtrR via insertion of the hspA promoter led to a delay in mortality caused by this strain. A loss of atrR rendered the resulting mutant strain avirulent, as reported before. In this model, loss of the abcG1 gene did not have an observable effect on virulence, contrary to results in found in a Galleria model of infection (16). These data argue that the precise level of AtrR is crucial for
FIG 8 AtrR binding and function at abcG1. (A) Three different abcG1-firefly luciferase (fLUC) reporter genes were integrated into the following three indicated isogenic genetic backgrounds: atrRΔ mutant, wt (atrR), and an AtrR-overproducing strain (hspA-atrR mutant) at the hisB locus. Representative transformants were grown to mid-log phase, whole-cell protein extracts were prepared, and levels of firefly luciferase were assayed using a standard method as described previously (14). The promoter sequence present is denoted as no-promoter (only fLUC cassette), 1 kb or 1.3 kb of abcG1 5’ noncoding DNA (relative to the ATG). P values are indicated as described in the Fig. 2 legend. (B) DNase I protection analysis using recombinant AtrR and a cloned segment of the abcG1 promoter (−1066 to −895 bp from the transcription start site) as a DNA probe. The protected regions are indicated on the sequence shown at the left in yellow boxes. The transcription start site is shown by the arrow, and the ATG and the start of the coding sequence for abcG1 (blue box) are indicated.
normal virulence. Normal pathogenesis thus requires a particular optimal dosage of AtrR with either elevated or depressed levels causing virulence defects in the animal model, a so-called “Goldilocks effect.”

**DISCUSSION**

Our identification of the ATRE as a component of the 34-bp region in the *cyp51A* promoter adds an important new element to an already crowded regulatory region. As seen for SRE1 (9), the ATRE is duplicated in the TR34 repeat, consistent with this AtrR being a key contributor to the elevated gene transcription found in the presence of this promoter alteration. A second common *cyp51A* promoter variant, called TR46 (26), would also contain two SREs and two ATREs, supporting the view that the duplication of binding sites for both of these factors is required for the observed increment in gene expression in both TR mutants. Further analysis of the TR34/46 duplications is required to determine which parts of these duplicated promoters are hyperactive. At least in the case of the TR34 promoter, although the CBC recognition site is duplicated, it does not

<table>
<thead>
<tr>
<th>Strain</th>
<th>Parent</th>
<th>Genotype</th>
<th>Reference or source</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF535</td>
<td>D141</td>
<td><em>akuAΔ::loxP</em></td>
<td>FGSC</td>
</tr>
<tr>
<td>SPF87</td>
<td>AF535</td>
<td><em>atrRΔ::ptrA</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF89</td>
<td>AF535</td>
<td><em>atrR::3×HA::hph</em></td>
<td>13</td>
</tr>
<tr>
<td>SPF108</td>
<td>AF535</td>
<td><em>ptrA::hspA-atrR</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF112</td>
<td>SPF89</td>
<td><em>ptrA::hspA-atrR::3×HA::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF84</td>
<td>AF535</td>
<td><em>abcG1Δ::loxP</em></td>
<td>16</td>
</tr>
<tr>
<td>SPF110</td>
<td>SPF84</td>
<td><em>abcG1Δ::ptrA::hspA-atrR</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF134</td>
<td>AF535</td>
<td><em>srbAΔ::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF137</td>
<td>SPF108</td>
<td><em>srbAΔ::ptrA::hspA-atrR</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF114</td>
<td>SPF87</td>
<td><em>atrRΔ::hisBΔ::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF116</td>
<td>SPF87</td>
<td><em>atrRΔ::hisBΔ::1kb abcG1::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF118</td>
<td>SPF87</td>
<td><em>atrRΔ::hisBΔ::1.3kb abcG1::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF119</td>
<td>AF535</td>
<td><em>hisBΔ::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF121</td>
<td>AF535</td>
<td><em>hisBΔ::1kb abcG1::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF123</td>
<td>AF535</td>
<td><em>hisBΔ::1.3kb abcG1::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF124</td>
<td>SPF108</td>
<td><em>hspA-atrR::hisBΔ::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF126</td>
<td>SPF108</td>
<td><em>hspA-atrR::hisBΔ::1kb abcG1::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF128</td>
<td>SPF108</td>
<td><em>hspA-atrR::hisBΔ::1.3kb abcG1::FLUC::hph</em></td>
<td>This study</td>
</tr>
<tr>
<td>SPF134</td>
<td>SPF108</td>
<td><em>hspA-atrR::hisBΔ::1kb abcG1::FLUC::hph</em></td>
<td>This study</td>
</tr>
</tbody>
</table>

**FIG 9** Effect of *atrR* alleles and *abcG1Δ* mutation on virulence. Eight mice per strain of *A. fumigatus* were immunosuppressed with cortisone acetate and then infected in an aerosol chamber and monitored for survival. Note that PBS control data are not distinguishable from *atrRΔ* infection. *P* for this experiment, <0.0001, *P* for pairwise comparison of *hspA-atrR* and wt = 0.03, by the log-rank rank sum test.
appear to be a functional binding site (9). This suggests that only the downstream CBC/HapX-repressive interaction is operational and possibly that the upstream duplicated 34-bp region is free of this normal repression.

The steady-state accumulation of AtrR at the protein level is sensitive to the form of this factor that is produced. The presence of the 3× HA epitope tag at the C terminus of AtrR caused the protein to behave as a hypermorphic allele and to exhibit lowered steady-state levels compared to the wild-type factor. Even when atrR-3× HA is driven by the hspA promoter, the resulting steady-state level is almost the same as when driven by the native atrR promoter. We cannot eliminate the possibility that replacement of the wild-type atrR promoter with that of the much stronger hspA element fails to increase the transcription of atrR-3× HA, although this is seen to occur in a comparison of wild-type atrR and hspA-atrR. Hyperactive transcription factors have been associated with more rapid degradation through ubiquitin-dependent means (27), and we speculate that this is true for the AtrR-3× HA protein. These data are consistent with the insertion of the 3× HA tag causing some alteration in the structure of AtrR that blocks proper control by a presumptive negative regulatory signal. We argue that since the expression level of AtrR is not increased at the protein or mRNA level, the elevated transcription rate that the AtrR-3× HA supports is due to a change in the activity of this protein. Similarly, elevated expression of the native factor appears to exceed the capacity of this negative regulation to restrain the transcriptional activation of AtrR. These suggestions are consistent with the hypothesis that the cause of hyperactivity of these two different atrR alleles is not the same. Both of these observations are consistent with the notion that AtrR is normally subject to negative regulation.

The large number of genes containing ChIP-seq peaks corresponding to AtrR was an unexpected observation. Earlier work identified approximately 120 genes as containing SREs and being transcriptionally responsive to SrbA (18, 22). Our ChIP-seq analysis detected nearly 900 genes with a significant association with AtrR, but fewer than 20% of these were induced in the presence of either hypermorphic allele of atrR used. Approximately 200 (atrR-3× HA) or 600 (hspA-atrR) genes were respectively induced in hypermorphic atrR backgrounds, but a minority of these induced genes contained ATREs. This is most readily interpreted by the majority of the transcriptional induction seen in these strains resulting from indirect effects. We hypothesize that AtrR occupies a relatively upstream position in the network of transcription factors that impact gene regulation in A. fumigatus, as supported by the GO term enrichment for these factors in the ChIP-seq data (Table S1). When AtrR is activated, it can induce the expression and function of a number of other transcriptional regulatory proteins and the circuits they directly control. We suggest that the full spectrum of transcriptional responses to changes in AtrR activity consist of a relatively smaller number of direct target genes (i.e., abcG1 and cyp51A) and a larger collection of genes that are activated via AtrR control of genes encoding other transcription factors (i.e., srbA and srbB).

While our data strongly support the ability of a sequence element with the CGG(N)12CCG as being sufficient to function as an ATRE in vivo, this single consensus is not sufficient to explain the entire range of target genes bound by AtrR. As can be seen in Table 2 and Fig. 3B, the precise consensus for in vivo ATREs is likely to be more complex and will require further characterization. Our finding of the important tandem ATREs located more than 1 kb upstream of the ATG in abcG1 illustrates the potentially increased complexity for A. fumigatus promoter organization compared to similar regions in more extensively characterized fungi, such as Saccharomyces cerevisiae (reviewed in reference 28).

Finally, the hypovirulent phenotype caused by either loss of atrR or overproduction of the wild-type factor illustrates the importance of the dosage of AtrR during pathogenesis. The normal disease process required a properly metered level of this protein and suggests that interventions targeting the activity of this transcriptional regulator might be effective in interfering with the pathogenicity of this important fungus. The essential role AtrR plays in azole resistance would also be impacted by interfering with
normal function of this transcription factor. Recent experiments describing the successful identification of a drug preventing normal transcription factor activation (29) suggest that this strategy might be effective to reduce AtrR-dependent transactivation as well. Further understanding of the molecular details explaining AtrR control of gene expression is essential to develop strategies to accomplish this goal.

MATERIALS AND METHODS

Strains and growth conditions. All strains used in this study were derived from the AF535 (FGSC #A1159) strain and are listed in Table 1. A. fumigatus strains were typically grown at 37°C in rich medium (Sabouraud dextrose; 0.5% tryptone, 0.5% peptone, 2% dextrose [pH 5.6 ± 0.2]). Selection of transformants was made in minimal medium (MM; 1% glucose, nitrate salts, trace elements, 2% agar [pH 6.5]); trace elements, vitamins, and nitrate salts are as described in the appendix of reference 30, supplemented with 1% sorbitol and either 200 mg/liter hygromycin Gold (InvivoGen) or 0.1 mg/liter pyrimethamine. For solid medium, 1.5% agar was added. For both ChIP- and RNA-seq experiments, all cells were cultured on rich Sabouraud dextrose medium as biofilms prior to the isolation of either fixed chromatin or RNA, respectively.

Derivatives containing the hspA-atrR construct were made as follows: 4 DNA fragments consisting of 1,000 bp upstream of the atrR coding sequence, β-ef/six-prA blaster cassette (from pSK485), hspA promoter, and 1,000 bp corresponding to the atrR 5’ coding sequence were joined by Gibson assembly at the BamH1 site of pUC19 to form pSP99. This plasmid was then digested with SmaI and PmeI to release the 8.5-kb integration construct from the plasmid backbone and transformed into AF535, SPF89, and SPF844 to generate strains SPF108, SPF112, and SPF110, respectively, under pyrimethamine selection. The srbAΔ disruption strain was generated using a hygromycin split-marker strategy (31). The split-marker cassettes were constructed by fusion PCR. The upstream split marker had a 1.2-kb region corresponding to the DNA segment immediately upstream of the srbA gene, followed by a partial hygromycin cassette. The downstream split marker had a 1.2-kb DNA fragment corresponding to the region immediately downstream of the srbA gene preceded by the complementary partial hygromycin cassette. The hygromycin partial cassettes contained a 600-bp overlap between the split markers. The upstream and downstream split markers were cotransformed into the AF535 and the SPF108 strain backgrounds to generate SPF134 and SPF137, respectively.

The abcG1 promoter-luciferase strains were generated as follows: an A. fumigatus his8 (AFu6g04700) targeting construct was initially made in a pRS316 vector backbone containing 1.2 kb DNA upstream of the his8 gene, the complete hygromycin cassette, firefly luciferase gene (from the pGL3 plasmid [Promega Corp., Madison, WI]), and 1.2-kb DNA downstream of the his8 gene using Gibson assembly. This plasmid was named pSP62 and was digested with Pmel and Ascl to insert either the 1-kb or 1.3-kb abcG1 promoter fragment just upstream of the luciferase reporter gene to generate pSP101a and pSP101b. The pSP62, pSP100a, and pSP100b plasmids were digested with NotI and KpnI to release the integration construct from the vector and transformed in AF535 and SPF108 strain backgrounds to generate SPF134 and SPF137, respectively.

The srbAΔ disruption strain was generated using a hygromycin split-marker strategy (31). The split-marker cassettes were constructed by fusion PCR. The upstream split marker had a 1.2-kb region corresponding to the DNA segment immediately upstream of the srbA gene, followed by a partial hygromycin cassette. The downstream split marker had a 1.2-kb DNA fragment corresponding to the region immediately downstream of the srbA gene preceded by the complementary partial hygromycin cassette. The hygromycin partial cassettes contained a 600-bp overlap between the split markers. The upstream and downstream split markers were cotransformed into the AF535 and the SPF108 strain backgrounds to generate SPF134 and SPF137, respectively.

The ABCG1 promoter-luciferase strains were generated as follows: an A. fumigatus his8 (AFu6g04700) targeting construct was initially made in a pRS316 vector backbone containing 1.2 kb DNA upstream of the his8 gene, the complete hygromycin cassette, firefly luciferase gene (from the pGL3 plasmid [Promega Corp., Madison, WI]), and 1.2-kb DNA downstream of the his8 gene using Gibson assembly. This plasmid was named pSP62 and was digested with Pmel and Ascl to insert either the 1-kb or 1.3-kb ABCG1 promoter fragment just upstream of the luciferase reporter gene to generate pSP101a and pSP101b. The pSP62, pSP100a, and pSP100b plasmids were digested with NotI and KpnI to release the integration construct from the vector and transformed in AF535 and SPF108 strain backgrounds to generate the different transcriptional fusion reporter strains given in Table 1.

Drug diffusion/spot assay. Fresh spores of A. fumigatus were suspended in 1× phosphate-buffered saline (PBS) supplemented with 0.01% Tween 20 (1× PBST). The spore suspension was counted using a hemocytometer to determine the spore concentration. Spores were then appropriately diluted in 1× PBST. For the drug diffusion assay, ~106 spores were mixed with 10 ml soft agar (0.7%) and poured over 15 ml regular agar containing (1.5%) minimal medium. A paper disk was placed on the center of the plate, and 10 μl of either 1 mg/liter voriconazole or 20 μg/liter fluconazole was spotted onto the filter paper. For the spot assay, ~100 spores (in 4 μl) were spotted on minimal medium with or without the drug. The plates were incubated at 37°C and inspected for growth every 12 h.

Generation of an AtrR antibody. A region of 597 bp (corresponding to the 199 N-terminal amino acids from atrR) were PCR amplified and cloned in frame as BamH1/SalI fragments downstream of the 6×-His tag in pET28a+ (EMD Millipore, Inc.) to form pG13 and transformed into the bacterial strain Escherichia coli BL21(DE3). Two liters of transformed bacteria was grown to log phase and induced with isopropyl-β-D-thiogalactopyranoside (IPTG) for 90 min. Cell lysates were prepared using a French press. Protein purification was accomplished using Talon metal affinity resin (Takara Bio USA, Inc.) as described.

### Table 2 ATREs from selected genesa

<table>
<thead>
<tr>
<th>Upstream endpoint</th>
<th>ATRE</th>
<th>Downstream endpoint</th>
<th>Locus</th>
</tr>
</thead>
<tbody>
<tr>
<td>−308</td>
<td>CGGATGTGTGCGGCCGG</td>
<td>−291</td>
<td>cypS1A</td>
</tr>
<tr>
<td>−842</td>
<td>CGGGTTAACCGCGTTCCG</td>
<td>−825</td>
<td>atrR</td>
</tr>
<tr>
<td>−1132</td>
<td>CGGACCTACAGATCCGA</td>
<td>−1114</td>
<td>abcG1</td>
</tr>
<tr>
<td>−1183</td>
<td>CGGATCAGTTAGATCCCG</td>
<td>−1166</td>
<td></td>
</tr>
<tr>
<td>−754</td>
<td>CGGAATCTTCTTCCCGG</td>
<td>−737</td>
<td>srbA</td>
</tr>
<tr>
<td>−617</td>
<td>CGGTATCCTAGATAGCG</td>
<td>−600</td>
<td>ergG</td>
</tr>
<tr>
<td>−730</td>
<td>CGAGTTCGTCATCAACCG</td>
<td>−753</td>
<td>ergG</td>
</tr>
<tr>
<td>−1081</td>
<td>CGGCATCTGGAATTCCG</td>
<td>−1064</td>
<td>ergG</td>
</tr>
</tbody>
</table>

aNumbers refer to distance upstream of the respective ATG, while the bolded letters indicate the conserved triplet.
by the manufacturer. Protein fractions were analyzed by staining them with Coomassie blue and by Western blotting using His-specific antibodies. The purified proteins were then lyophilized and sent to Pacific Immunology (Ramona, CA) for injection into rabbits to generate polyclonal antibodies against AtrR. Antiserum generated from these rabbits was received and tested for immunoreactivity against A. fumigatus cell lysates. The antiserum was then purified using an AminoLink Plus coupling resin (Thermo Scientific, Inc.) according to the manufacturer's instructions, and the affinity-purified antiserum was used to detect the AtrR protein from A. fumigatus cell lysates.

**Western blotting.** Western blotting was performed as described in reference 32. The rabbit AtrR polyclonal antibody was used at a 1:100 dilution, while the anti-AbcG1 antibody was used at a 1:1,000 dilution.

**Real-time PCR.** Quantitative reverse transcription-PCR (qRT-PCR) was performed as described in reference 32, with the exception that cell lysates were prepared from mycelial biofilm cultures formed upon inoculating 10⁴ spores in a petri dish containing 20 ml of Sabouraud dextrose broth and grown for 24 h at 37°C under nonshaking conditions. The threshold cycle (Cₜ) value of the act1 transcript was used as a normalization control.

**ChIP-seq.** Chromatin immunoprecipitation (ChIP) was done as described in reference 13. Purified ChIP-ed DNA was then subjected to library preparation as outlined in reference 33, with the following modifications. The purified ChIP-ed DNA was concentrated to 10 μl using a SpeedVac system and the libraries set up using the Rubicon ThruPLEX DNA-seq kit with 10 μl as the input volume. The paired reads were mapped to the AF293 A. fumigatus genome using Bowtie 2 (34). The MACS2 algorithm was used to call significant read depth peaks upon comparing epitope-tagged samples to the untagged wild-type control (35). ChIP-seq peaks were analyzed for proximity to annotated protein-coding genes using the ChIPPeakAnno package (36). A fasta file was generated containing 250 bp on either side of significant peaks and was used for conserved motifs using MEME-Chip (37). A summary of all next-generation sequencing (NGS) data (ChIP- and RNA-seq) is provided in Table S2.

**RNA-seq.** RNA was prepared as described in reference 32, with the exception that cell lysates for RNA were prepared as described above for generating samples for qRT-PCR. RNA samples were quantified using fluorometry, and RNA quality was assessed using the Agilent 2100 Bioanalyzer. Sequencing libraries were generated using the TruSeq stranded mRNA sample preparation kit (Illumina, Inc., San Diego, CA) and following Illumina's sample preparation guide, with 500 ng of input total RNA. The molar concentrations of the indexed libraries were measured using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) with a high-sensitivity chip, and the libraries were combined equally into one pool. The molar concentration of the pool was measured using the Kapa Illumina library quantification kit (Kapa Biosystems, Wilmington, MA), and the pool was sequenced on one lane of the Illumina HiSeq 4000 sequencer with 75-bp paired-end SBS chemistry (Illumina). Paired-end reads were mapped to the AF293 A. fumigatus genome using HISAT2 (38). Transcript assembly, quantification of expression levels, and analysis of differential expression were done using StringTie and Ballgown (39).

**EMSA.** Radiolabeled EMSA was performed using the protocol described in reference 40, with the following modifications: a probe corresponding to the cyp51A promoter was PCR amplified using the GAAATAACCTGATGGATATAATCGC (sense [S]) and CATGCTGATTTTATATTACCTACCC (antisense [AS]) primer pair. This region contained the 34 bp that is duplicated in the cyp51A TR₃₄ allele and is associated with clinically relevant azole-resistant strains. The atrR probe was amplified using the CTAGATCCTGGAGTCGACTGCCTC (S) and GCAGTCAATACCAATCGACTGGG (AS) primer pair, the abcG1 probe amplified using the GTTCGGGATATATCATCGTTCTG (S) and GTGACAAATCCGGCTAGCA (AS) primer pair, and the srbA probe amplified using the ATGGTGTAAGCAGGATCGATACAGCC (S) and GAATTTCGCTGCGCCGAG (AS) primer pair. All of these probes were designed such that they corresponded to the AtrR ChIP-seq peak region for their respective promoters. Aliquots of each probe were end-labeled with α-[32P]-ATP and T4 polynucleotide kinase. For competitive binding, 40-fold molar excess of the nonradiolabeled probe was added to the binding reaction.

Biotin-labeled EMSA was performed as follows: biotin-labeled oligonucleotides used in the reaction corresponded to the 34-bp sequence in the cyp51A promoter that is duplicated (TR₃₄) in many drug-resistant clinical isolates and were ordered from IDT (Coralville, IA). The sense strands of the competitor nonlabeled oligonucleotides were listed in Fig. 7B. The complementary strands of the labeled and unlabeled oligonucleotides were annealed by heating at 95°C and gradual cooling to room temperature prior to use as probes. The binding reaction for recombinant AtrR-DNA binding domain (AtrR-DBD; 0.1 μg/reaction) was done in the presence of 25 mM Tris-HCl (pH 7.5), 80 mM NaCl, 35 mM KCl, 5 mM MgCl₂, 10% glycerol, and 1 μg poly(dI-dC) in a 20-μl reaction volume. Twenty picomoles biotinylated probe was used per reaction. When nonlabeled probes were used, they were in 12-fold molar excess to the labeled probe. Incubation was done at room temperature for 30 min. DNA and protein-DNA complexes were resolved by electrophoresis at 100 V on a 5% native acrylamide gel at room temperature using a buffer containing 45 mM Tris (pH 8.0), 45 mM boric acid, and 1 mM EDTA (TBE). DNA was electrophoretically transferred from the gel to a nylon membrane (Hybond-N + Amersham) in 0.5× TBE buffer at 100 V for 30 min. The membrane was then blocked in 1% SDS in Odyssey blocking buffer (PBS) for 30 min, replaced with fresh blocking buffer plus 1% SDS, and incubated in 10,000 streptavidin-680 nm IRDye (Li-Cor) for 30 min at room temperature. The membrane was then washed three times in 1× PBST for 5 min each, followed by scanning using a Li-Cor Odyssey infrared imaging system, application software version 3.0, and quantified using the Image Studio Lite 4.0 software (Li-Cor).

**DNase I footprinting.** DNase I footprinting assay was carried out as described in reference 40, with the following modifications: for generation of the cyp51A probe, a PCR product corresponding to 453 to 191 bp upstream of the translation start site containing the 34 bp duplicated in TR₃₄ was cloned into...
pCR2.1-TOPO. This plasmid was digested with Sall, treated with calf intestinal alkaline phosphatase, phosphorylated with T4 polynucleotide kinase and [γ-32P]-ATP, and finally cleaved with HindIII. For generation of the abcG1 probe, a PCR product of the abcG1 promoter containing 1,210 to 1,039 bp upstream of the abcG1 translation start site, including the ChiP-seq peak region, was cloned into pCR2.1-TOPO. This plasmid was digested with Sall, treated with calf intestinal alkaline phosphatase, phosphorylated with T4 polynucleotide kinase and [γ-32P]-ATP, and finally cleaved with Mlu.

**Luciferase assay.** Firefly luciferase assays were done using the firefly luciferase assay kit procured from Biotium, Inc., as described in reference 14.

**Mouse model of invasive aspergillosis.** To investigate the virulence of various strains, we used a nonneutropenic mouse model of invasive aspergillosis (41). Briefly, 6-week-old and 20- to 22-g male BALB/c mice (Taconic Laboratories) were immunosuppressed with 7.5 mg cortisone acetate (Sigma-Aldrich) administered subcutaneously every day from day 4 before infection to day 4 after infection, for a total of 5 doses. To prevent bacterial infection, enrofloxacin (Baytril; Western Medical Supply) was added to the drinking water at a final concentration of 0.005% the day before beginning the cortisone acetate treatment. Next, 11 to 12 mice per group were infected in an acrylic chamber exposing them for 1 h to an aerosol generated from 12 ml of PBS containing 109 conidia/ml. Immediately after infection, 3 mice from each group were sacrificed, and lungs were harvested, homogenized, and quantitatively cultured to verify the delivery of conidia to the lungs. The remaining mice were monitored twice daily for survival assessment. As a negative control, 8 mice were immunosuppressed but not infected.

**Data availability.** All NGS data are available as a linked GEO SuperSeries accession number GSE123446.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at [https://doi.org/10.1128/mBio.02563-18](https://doi.org/10.1128/mBio.02563-18).

**FIG S1, PDF file, 0.8 MB.**

**FIG S2, PDF file, 0.8 MB.**

**TABLE S1, XLSX file, 0.1 MB.**

**TABLE S2, XLSX file, 0.9 MB.**

**ACKNOWLEDGMENTS**

This work was supported in part by NIH grant GM49825 to W.S.M.-R., grant AI13748 to W.S.M.-R. and Paul Bowyer, and NIH grant AI124566 to S.G.F.

We thank Robert Cramer, Hubertus Haas, Paul Bowyer, and Mike Bromley for helpful discussions and sharing unpublished information. We also thank Damian Krysan for a critical reading of the manuscript.

**REFERENCES**


